Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Low/Int-1 Risk MDS with Thrombocytopenia (EUROPE)
NCT02335268Phase 2Completed
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie
- Start
- May 2015
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of romiplostim in myelodysplastic syndrome (MDS), sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie. Started May 2015; status: completed.
02
Drugs
romiplostim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02335268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335268.